Appili Therapeutics – Press Release Correction
23 Junho 2023 - 6:07PM
Business Wire
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company”
or “Appili”), announced today a correction to its press release
entitled “Appili Therapeutics Reports Fiscal Year 2023 Financial
and Operational Results” which was issued on June 23, 2023 (the
“Initial Press Release”).
The Initial Press Release, under the heading entitled “ATI-1501,
with Patent Coverage through 2039” incorrectly stated that it is
expected that the FDA review will be complete in Q3 2024. The
correct expected date that the FDA review will be complete is Q3
2023.
The Initial Press Release also incorrectly stated that The
Company expects to receive milestone payments in Q3 2024 and Q4
2024 based on Saptalis’ proposed NDA submission timeline and
commercialization plans. The correct expected date to receive
milestone payments is Q3 2023 and Q4 2023.
This Press Release should be read in conjunction with the
Initial Press Release and is subject to the forward looking
statement disclaimer set out in the Initial Press Release. These
corrections do not change any other information reported in the
Initial Press Release.
About Appili Therapeutics Appili Therapeutics is an
infectious disease biopharmaceutical company that is purposefully
built, portfolio-driven, and people-focused to fulfill its mission
of solving life-threatening infections. By systematically
identifying urgent infections with unmet needs, Appili’s goal is to
strategically develop a pipeline of novel therapies to prevent
deaths and improve lives. The Company is currently advancing a
diverse range of anti-infectives, including a vaccine candidate to
eliminate a serious biological weapon threat, a topical
antiparasitic for the treatment of a disfiguring disease, and a
novel easy to use, liquid oral formulation targeting parasitic and
anaerobic infections. Led by a proven management team, Appili is at
the epicenter of the global fight against infection. For more
information, visit www.AppiliTherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230623613835/en/
Media: Jenna McNeil, Communications Manager Appili
Therapeutics JMcNeil@AppiliTherapeutics.com
Investor Relations: Don Cilla, President and CEO Appili
Therapeutics Info@AppiliTherapeutics.com
Appili Therapeutics (TSX:APLI)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Appili Therapeutics (TSX:APLI)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024